Literature DB >> 19085457

Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana.

Marçal Mariné1, F Javier Pastor, Josep Guarro.   

Abstract

We tested ten day courses of amphotericin B (AMB), micafungin (MFG), voriconazole (VRC), flucytosine (5FC) and posaconazole (PSC) alone and in double or triple combinations in the treatment of disseminated infections caused by Cladophialophora bantiana in a murine model. Animals were monitored for survival for 40 days. We found that PSC at 100 mg/kg or 5FC at 180 mg/kg prolonged survival over controls. The combinations PSC+MFG and PSC+5FC improved survival compared to MFG and 5FC alone, but were not superior to PSC alone. The triple combination of PSC+MFG+5FC improved the survival with respect to both the control group and the component monotherapies, but all the animals died during the experiment. When treatment with this triple therapy was extended up to 30 days, half of the animals survived for at least 10 months. Combination therapy with the three drugs (PSC, MFG and 5FC) appears to be a promising option for the treatment of C. bantiana infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19085457     DOI: 10.1080/13693780802526840

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  13 in total

1.  Disseminated Cladophialophora bantiana disease in a patient with prediabetes.

Authors:  Anas Mansour; Kim Jordan
Journal:  BMJ Case Rep       Date:  2014-11-14

2.  Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.

Authors:  S Seyedmousavi; K Samerpitak; A J M M Rijs; W J G Melchers; J W Mouton; P E Verweij; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 3.  Black yeasts and their filamentous relatives: principles of pathogenesis and host defense.

Authors:  Seyedmojtaba Seyedmousavi; Mihai G Netea; Johan W Mouton; Willem J G Melchers; Paul E Verweij; G Sybren de Hoog
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.

Authors:  Enrique Calvo; F Javier Pastor; Emilio Mayayo; Pilar Hernández; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.

Authors:  Hamid Badali; G Sybren de Hoog; Ilse Curfs-Breuker; Corné H W Klaassen; Jacques F Meis
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

Review 6.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Emilio Mayayo; Valentina Salas; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

8.  Cladophialophora bantiana brain abscess in an immunocompetent patient.

Authors:  Sanjay G Revankar
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

9.  Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.

Authors:  S Deng; W Pan; W Liao; G S de Hoog; A H G Gerrits van den Ende; R G Vitale; H Rafati; M Ilkit; A H Van der Lee; A J M M Rijs; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

10.  Cladophialophora bantiana osteomyelitis in a renal transplant patient.

Authors:  Stefanie Desmet; Liesbeth Smets; Katrien Lagrou; Inge Derdelinckx; Jeroen Neyt; Johan Maertens; Raf Sciot; Philip Demaerel; Bert Bammens
Journal:  Med Mycol Case Rep       Date:  2016-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.